menu
    • menu
    [{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SPY003","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPY002-091","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Aeglea BioTherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Aeglea BioTherapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Spyre Therapeutics

    Menu

    Spyre Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPY003

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spyre Doses First Participant In Phase 1 Trial Of SPY003 IL-23 Antibody

                            Details : SPY003 is an investigational half-life extended anti-IL-23 monoclonal antibody, which is currently being evaluated for the treatment of inflammatory bowel disease.

                            Product Name : SPY003

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 27, 2025

                            Lead Product(s) : SPY003

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPY002-091

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spyre Starts Phase 1 Trials for Anti-TL1A Half-Life Extended Antibodies

                            Details : SPY002-091 is an investigational, extended half-life monoclonal antibody targeting TL1A for the potential treatment of inflammatory and fibrotic diseases including IBD.

                            Product Name : SPY002-091

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : SPY002-091

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPY001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spyre Doses First Patients in Phase 1 Trial, SPY001 for the Treatment of IBD

                            Details : SPY001 is an investigational novel half-life extended anti-α4β7 monoclonal antibody, which is being evaluated for the treatment of inflammatory bowel disease.

                            Product Name : SPY001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : SPY001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Spyre Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPY001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Aeglea BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

                            Details : Through the acquisition, Aeglea expands its inflammatory bowel disease portfolio by including, SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A, respectively.

                            Product Name : SPY001

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : SPY001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Aeglea BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth